Amoxicillin tablet price

Patients received either clarithromycin MR 500 mg once daily or amoxicillin/clavulanic acid 500 mg/125 mg three times daily for 7 days.

Primary endpoints were sponsor-defined clinical response and pathogen outcome at the end of treatment. Secondary endpoints were sponsor-defined clinical response and pathogen outcome at study end,

investigator-defined

Clinical and bacteriologic outcomes with both treatments for all endpoints were statistically equivalent, as were total adverse events, although the incidences of digestive disturbances (13% vs 4%) and discontinuations due to adverse events (8 vs 2 patients; P?.05) were significantly higher with amoxicillin/clavulanic acid.

Ninety-five percent of patients receiving clarithromycin MR and 80% receiving amoxicillin/clavulanic acid were 100% compliant with medication (P?.05). Clarithromycin MR and amoxicillin/clavulanic acid are both well tolerated and effective as therapy for AECB; however, clarithromycin produced fewer side effects and discontinuations and higher compliance rates. This is a preview of subscription content, log in to check access.

Evaluation and comparison of in-vitro dissolution profiles for different brands of amoxicillin capsules.

Amoxicillin is an oral semi-synthetic, ?-lactam antibiotic used to treat bacterial infections caused by susceptible micro organisms. It is usually prepared in capsule, tablet and powder for oral suspension form. Solid dosage forms for oral administration pose bioavailability problems related to the absorption process The World Health Organization (WHO) has promoted the use of generic brands in order to make the cost of medicines affordable. Generic substitution could be considered when a generic copy of a reference drug contains identical amounts of the same active ingredient in the same dose formulation and route of administration. However, the presences of generic products those are not interchangeable with that of the innovator and/or with each others have been reported.

To evaluate and compare the in-vitro dissolution profiles of different generic brands of amoxicillin capsules with the innovator that are available in Ethiopian market. Dissolution profiles for nine brands of amoxicillin capsules contained amoxicillin 500 mg which are available in Ethiopian market were determined using a method from the United States Pharmacopoeia (USP, 2009). The obtained dissolution profile data of the eight brands were evaluated and compared with the innovator brand (Amoxil™) using two different statistical methods: the fit factors (f1 & f2) and the dissolution efficiency (D.E.) model.

Most generic brands of amoxicillin capsules (62.5% of the tested brands) are not interchangeable with the innovator brand.

The calculated f1 factor for

Brand

However, for the rest six brands the f1 factors are greater than 15. The f2 factor for Brand G is 74.1 and for Brand A is 48.5 which is near to 50. Similarly, the f2 factors for the six brands are less than 50 which support the result of the f1 factors for the dissimilarity of these brands with the innovator brand.

The mean dissolution efficiencies as well as the 95% confidence intervals are within ±10% only for two brands, Brand F and Brand G. Most generic brands of amoxicillin capsules (62.5%) are not interchangeable with the innovator brand (Amoxil™).

Comparison between penetration of amoxicillin combined with carbocisteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue.

Research output : Contribution to journal › Article.

Patients with chronic bronchitis were treated orally with either amoxicillin (500 mg) alone or in combination with carbocisteine (150 mg), thrice daily for five days, in order to assess whether the combination allows higher antibiotic levels to be obtained in bronchial mucus than those obtained from amoxicillin alone. Serum and mucus levels were determined for each patient at first and fifth day of the two drug regimens. The levels of amoxicillin in the lung tissue collected in patients undergoing pulmonary surgery were also determined after a single oral dose of amoxicillin (1 g) or of amoxicillin (1 g) plus carbocisteine (300 mg). In the bronchial secretions, at the same plasma concentrations, amoxicillin levels were statistically higher after administration of combined substances.

These findings indicate the presence of a pharmacokinetic synergism between these compounds, which allows amoxicillin to penetrate more easily through the haematobronchial barrier.

The association of amoxicillin and carbocisteine, determining an increase of the quantitative levels of antibiotic in the bronchial secretion (also if it is purulent), performs a sterilizing action in a short time with significant therapeutic advantages. Original language English Pages (from-to) 331-340 Number of pages 10 Journal International Journal of Clinical Pharmacology Research Volume 5 Issue number amoxicillin 650 5 Publication status Published - 1985. Pharmacology (medical) Pharmacology, Toxicology and Pharmaceutics(all) Access to Document. Fingerprint Dive into the research topics of 'Comparison between penetration of amoxicillin combined with carbocisteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue'. Research output : Contribution to journal › Article.

T1 - Comparison between penetration of amoxicillin combined with carbocisteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue.

N2 - Patients with chronic bronchitis were treated orally with

either

Serum and mucus levels were determined for each patient at first and fifth day of the two drug regimens. The levels of amoxicillin in the lung tissue collected in patients undergoing pulmonary surgery were also determined after a single oral dose of amoxicillin (1 g) or of amoxicillin (1 g) plus carbocisteine (300 mg).

In the bronchial

secretions

AB - Patients with chronic bronchitis were treated orally with either amoxicillin (500 mg) alone or in combination with carbocisteine (150 mg), thrice daily for five days, in order to assess whether the combination allows higher antibiotic levels to be obtained in bronchial

mucus

concentrations

These findings indicate the presence of a pharmacokinetic synergism between these compounds, which allows amoxicillin to penetrate more easily through the haematobronchial barrier. The association of amoxicillin and carbocisteine, determining an increase of the quantitative levels of antibiotic in the bronchial secretion (also if it is purulent), performs a sterilizing action in a short time with significant therapeutic advantages.

JO - International Journal of Clinical Pharmacology Research. JF - International Journal of Clinical Pharmacology Research. What is the difference between Augmentin and amoxicillin? Augmentin and amoxicillin are two types of antibiotics. Antibiotics help treat bacterial infections that may be too strong for the body’s immune system to clear. Amoxicillin is a very common type of antibiotic, and Augmentin contains amoxicillin and clavulanate or clavulanic acid, which may make it more effective against some types of infection.

In this article, learn about the difference between the two antibiotics and the potential side effects of each. Share on Pinterest Doctors commonly prescribe Augmentin or amoxicillin for bacterial infections.

Augmentin and amoxicillin are both in the penicillin drug class, which is a group of common antibiotics.

Augmentin contains amoxicillin, as the primary ingredient, and it also contains clavulanate.

Clavulanate can help treat infections caused by antibiotic-resistant bacteria.

The two antibiotic drugs are generally the first line of defense against troublesome bacterial infections. It is important to note that these types of drugs do not

work

Taking antibiotics unnecessarily may make them less effective over time and lead to antibiotic resistance.